Recently, Li et al89 reviewed that targeting IKBKE with three TBK1/IKBKE dual inhibitors, including WO2009032861, SAR and Domainex, could powerfully inhibit cell viability and tumor development in human breast, prostate, and oral cancers both in vivo and in vitro. The gene discussed is IKBKE; the disease is neoplasm.